Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer

Molecular Carcinogenesis

Volumn 50, Issue 5, 2011, Pages 390-396

  Zuo, Qing Song ^a   Yan, Ronglin ^b   Feng, Dian Xu ^a   Zhao, Ronghua ^c   Chen, Chao ^a   Jiang, Yi Ming ^a   Cruz Correa, Marcia ^d   Casson, Alan G ^c   Kang, Xiang Dong ^a   Han, Feng ^a   Chen, Teng ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Gastric cancer; Insulin like growth factor II; Loss of imprinting

Indexed keywords

RESTRICTION ENDONUCLEASE; SOMATOMEDIN B;

ADULT; ARTICLE; CANCER SURVIVAL; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOME IMPRINTING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MOLECULAR PATHOLOGY; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMACH MUCOSA;

ADULT; AGED; FEMALE; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; LYMPHOCYTES; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 79953775098     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20731     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59.
3. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 2006;24:2188-2196.
4. Jelinic P, Shaw P. Loss of imprinting and cancer. J Pathol 2007;211:261-268.
5. Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers 2007;23:105-112.
6. Zhao R, Casson AG. Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer. Curr Cancer Drug Targets 2008;8:509-521.
7. Zhao R, Cruz-Correa M. Loss of imprinting of insulin-like growth factor 2 gene and risk of colorectal cancer. Curr Colorectal Cancer Rep 2008;4:65-70.
8. Feinberg AP. Genomic imprinting and cancer. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 1998.
9. Diaz-Meyer N, Day CD, Khatod K, et al. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet 2003;40:797-801.
10. Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis 2009;30:2117-2122.
11. Mori M, Inoue H, Shiraishi T, et al. Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer 1996;68:441-446.
12. Feagins LA, Susnow N, Zhang HY, et al. Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol 2006;290:G871-G875.
13. Xu W, Fan H, He X, Zhang J, Xie W. LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res 2006;25:543-547.
14. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science 2003;299:1753-1755.
15. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: A potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004;126:964-970.
16. Liou JM, Wu MS, Lin JT, et al. Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. Eur J Cancer 2007;43:1276-1282.
17. Sasaki J, Konishi F, Kawamura YJ, Kai T, Takata O, Tsukamoto T. Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2. Int J Cancer 2006;119:80-83.
18. Wu MS, Wang HP, Lin CC, et al. Loss of imprinting and overexpression of IGF2 gene in gastric adenocarcinoma. Cancer Lett 1997;120:9-14.
19. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005;92:1644-1649.
20. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998;4:1276-1280.
21. Lu Y, Lu P, Zhu Z, Xu H, Zhu X. Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer. J Exp Clin Cancer Res 2009;28:125.
22. Cruz-Correa M, Zhao R, Oviedo M, et al. Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene. Epigenetics 2009;4:114-118.
23. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
24. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.
25. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 2007;28:20-47.
26. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
27. Hopkins A, Crowe PJ, Yang JL. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol 2010;136:639-650.
28. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16:2512-2517.
29. Min Y, Adachi Y, Yamamoto H, et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005;54:591-600.
30. Pavelic K, Kolak T, Kapitanovic S, et al. Gastric cancer: The role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 2003;201:430-438.
31. Jiang Y, Wang L, Gong W, et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 2004;21:755-764.
32. Matsubara J, Yamada Y, Hirashima Y, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res 2008;14:3022-3029.
33. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005;307:1976-1978.
34. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001;93:1698-1703.
35. Woodson K, Flood A, Green L, et al. Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J Natl Cancer Inst 2004;96:407-410.
36. Kaneda A, Wang CJ, Cheong R, et al. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 2007;104:20926-20931.
37. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.